Novel diurea lead compounds that block intracellular signal transduction and inhibit interleukin-2 production and other pro-inflammatory cytokines in T-cells, and promote activation-induced cell death (apoptosis) for treatment of inflammatory diseases. These compounds were discovered in a screening process for novel signal transduction inhibitors with the ability to block the production of IL-2 and other pro- inflammatory cytokines in activated T-cells. The aim is to develop a new anti-inflammatory drug for the treatment of conditions involving chronic inflammation such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The diurea compounds are potent inhibitors of IL-2 production in human CD4+ T-cells. They display IC50 values in the range of 1 micro M in cell-based assays. Proof of concept in vivo has been obtained demonstrating significant inhibition of IL-2 production induced by superantigen.

A priority patent application has been filed 2004-02- 04, which claims protection for novel diurea compounds, that inhibit the production of pro-inflammatory cytokines and/or induce apoptosis in activated T-cells, use of such a compound as a medicament, a pharmaceutical composition comprising said compounds and a method of treatment. At the same date a provisional US patent application was filed. Status: Pending applications. Expected expiry date: 2025.

Active Biotech seeks an early strategic partnership for this project. The partner should have experience in the disease areas to ensure professional and timely development of the compound. Terms of agreement can be flexible and discussed.